Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates

The Manila Times

Firefly Neuroscience reported a 373% year-over-year increase in U18 ADHD Evoke™ scans, driven by growing clinical adoption and commercial expansion. The company is leveraging its nationwide network to cross-sell non-drug ADHD treatments, aiming to create an end-to-end diagnostic-to-treatment model. The surge in scans also enhances Firefly's AI foundation through its expanding proprietary dataset of over 200,000 brain scans.

Read at The Manila Times

All articles from 17 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.

Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.

More to read